Kidney Cell Carcinoma Articles & Analysis
18 news found
The study was conducted as a collaboration between Atrium Health Levine Cancer Institute, Sanofi, and GeneCentric and evaluated real-world data from patients diagnosed with renal cell carcinoma (RCC) who were treated with immune-oncology agents. Results suggest that common and distinct immune-related response markers for IL-2 and anti-PD-(L)1 therapy may help ...
AFM13 monotherapy: Completed enrollment in the REDIRECT study for patients with relapsed or refractory PTCL; on track to report topline data in the fourth quarter of 2022 AFM13 combination with NK cells: Reported data at AACR 2022 showing a 100% objective response rate (ORR) and an increase in complete responses (CR) from 38%, reported in December, to 62% after a second cycle of therapy in 13 ...
Design and rationale of the phase 1/2a open label, multicenter study of the AFM24 monotherapy in patients with advanced EGFR-expressing solid tumors Design and rationale of the phase 1/2a study of AFM24 in combination with atezolizumab in patients with advanced EGFR-expressing solid tumors Design and rationale of the phase 1/2a study of AFM24 in combination with SNK01 autologous natural ...
In the clinical trial, 30 patients with metastatic kidney cancer (renal cell carcinoma) who had never received treatment before were randomized to receive either CBM588 orally in combination with nivolumab/ipilimumab or nivolumab/ipilimumab alone. ...
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 9:20 a.m. eastern time. A live webcast of the fireside chat can be accessed by visiting the investors section of ...
INDICATIONS FOTIVDA is indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. ...
NiKang Therapeutics Inc. (“NiKang”), a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs and AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company (“AVEO”) , today announced that they have entered into a clinical trial collaboration and supply ...
INDICATIONS FOTIVDA is indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. ...
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany to evaluate ficlatuzumab in combination with ERBITUX® (cetuximab), an EGFR-targeted antibody, in patients with recurrent or metastatic head and neck squamous cell carcinoma ...
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will participate in the H.C. Wainwright Virtual BioConnect 2022 Conference, which is taking place from Monday, January 10th to Thursday, January 13th. A webcast of the fireside chat with AVEO’s management team and H.C. Wainwright research ...
City of Hope®, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases, and Osel, Inc., a company developing live biotherapeutic products (LBPs) for diseases linked to the disruption of the human microbiome, today announced that City of Hope has granted an exclusive worldwide license to Osel for intellectual property on the novel use ...
Osel Inc., a company developing live biotherapeutic products (LBPs) for diseases linked to the disruption of the human microbiome, announced today that City of Hope, a world-renowned independent cancer and diabetes research and treatment center, presented data from a Phase 1b trial showing that an LBP, CBM588 (Clostridium butyricum MIYAIRI 588® strain), plus nivolumab/ipilimumab improved ...
AVEO Oncology (Nasdaq: AVEO) today announced that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines to include FOTIVDA® (tivozanib) as a recommended regimen for subsequent therapy. The subsequent therapy category follows the first-line treatment regimen recommendations for patients with clear cell histology renal cell carcinoma (ccRCC). On March 10, ...
Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval for Cabometyx® (cabozantinib) in combination with Bristol Myers Squibb’s Opdivo® (nivolumab) for the first-line treatment of advanced renal cell carcinoma (aRCC). The European Commission, which has the ...
Immunotech Biopharm Ltd will have rights to develop and commercialize 800TCR, a HERV-E targeting T cell receptor (TCR) therapy for the treatment of kidney cancer, in China T- Cure Bioscience to receive an upfront payment and future development milestones and royalties Sherman Oaks, CA – January 20, 2021 – T-Cure Bioscience, Inc., a privately ...
Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology company, announced that the NIH awarded CTT $1.44M on the second year of a competitive Small Business Innovation Research (SBIR) Phase IIB grant. The three year grant commenced in 2019 and totals $3.3M and this second year of funding supports the current CTT1403 clinical trial. The clinical trial, conducted at ...
“For more than 12 years, Pfizer has led the field in its commitment to developing new treatments for patients with advanced kidney cancer.” “With today’s FDA approval of BAVENCIO in combination with axitinib, we feel privileged that we can offer patients with first-line advanced renal cell carcinoma a new treatment ...
TVAX Biomedical, a clinical stage development company advancing its proprietary T cell-based immunotherapy for the treatment of cancer, today announced the decision of the board to hire Dr. ...